
The FY2027 appropriations process gives Congress an immediate opportunity to protect medical cannabis patients from discrimination while addressing the gaps left by the Attorney General's order. Through funding directives, legislative provisions, and committee report language, Congress can require federal agencies to protect patients, update outdated policies, and establish the safeguards necessary for safe access and healthcare integration. These actions cannot replace comprehensive medical cannabis legislation, but they can help ensure that patients are not left behind while Congress develops a national framework.
For ASA's complete appropriations agenda, detailed requests across all seven subcommittees, and the latest congressional developments, visit our FY2027 Medical Cannabis Appropriations Hub. The hub will be updated as Congress considers FY2027 funding legislation and patient advocacy opportunities.
DOWNLOAD PROPOSED OPM APPROPS LANGUAGE | TAKE ACTION
WHY FINANCIAL SERVICES & GENERAL GOVERNMENT MUST ACT
Federal employment rules have not kept pace with the developing federal medical cannabis framework. A cannabis-positive workplace test can establish exposure to a cannabinoid without establishing when it was consumed, whether a person was impaired while working, or whether work performance or safety was affected. Federal employees, applicants, and workers employed by federal contractors may nevertheless face employment consequences under differing personnel, suitability, testing, and drug-free workplace requirements.
Federal protections and restrictions must be distinguished carefully. Section 501 of the Rehabilitation Act governs disability discrimination in federal employment and incorporates Americans with Disabilities Act (ADA) employment standards; Section 503 addresses disability protections for covered federal contractors. Yet the ADA contains exceptions relating to current illegal drug use, Executive Order 12564 establishes federal drug-free workplace requirements, and other statutes and security rules apply to particular jobs. Participation in a state medical cannabis program does not, on its own, create an exemption from these requirements or automatically establish a legally protected accommodation.
The Attorney General’s April 2026 order changed the scheduling treatment of qualifying medical cannabis products but did not independently revise federal employment requirements. Congress should direct the Office of Personnel Management (OPM), working with the Department of Health and Human Services (HHS), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the Department of Justice (DOJ), to clarify the evidentiary limits of positive tests, support individualized evaluation where legally permitted, protect sensitive medical information, and identify restrictions that require statutory or executive action. The review must preserve legitimate safety, national security, and operational requirements while distinguishing federal employees from workers subject to separate federal contractor rules.
ASA'S FY2027 APPROPRIATIONS REQUEST |
Americans for Safe Access requests that Congress direct the Office of Personnel Management (OPM), in consultation with the Department of Health and Human Services (HHS), the Substance Abuse and Mental Health Services Administration (SAMHSA), and the Department of Justice (DOJ), to issue federal workplace medical cannabis guidance within 30 days of enactment and complete an interagency policy review and report to Congress within 180 days. Congress can accomplish these objectives through either statutory language or committee report directives.
The guidance should clarify that a cannabis-positive drug test, standing alone, does not establish current impairment, deficient job performance, or unsafe conduct, while recognizing that separate federal drug-use prohibitions, suitability requirements, and security standards may independently govern employment decisions. The interagency review should identify opportunities for individualized assessment, protect medical privacy, distinguish federal personnel policies from contractor requirements administered under separate authorities, and recommend changes necessary to protect medical cannabis patients while preserving legitimate workplace safety and security requirements.
Purpose: Federal workplace drug-testing policies often rely on cannabis-positive results that establish prior exposure but do not determine whether an employee is currently impaired or poses a workplace safety risk. As federal recognition of medical cannabis advances, Congress should ensure that federal employment policies reflect current scientific understanding, protect confidential medical information, and distinguish medical cannabis participation from evidence of impairment or deficient performance. Coordinated federal guidance and congressional oversight can identify outdated policies, clarify existing legal protections, and establish pathways for individualized assessment where permitted by law, while preserving applicable federal drug-use restrictions, suitability standards, national-security requirements, and legitimate workplace safeguards.
PROPOSED BILL LANGUAGE
SEC. __. FEDERAL WORKPLACE POLICY AND STATE-AUTHORIZED MEDICAL CANNABIS USE.
Not later than 30 days after the date of enactment of this Act, the Director of the Office of Personnel Management, in consultation with the Secretary of Health and Human Services, the Assistant Secretary for Mental Health and Substance Use, and the Attorney General, shall issue guidance to federal agencies regarding state-authorized medical cannabis participation and workplace drug-testing policies.

Such guidance shall clarify that a cannabis-positive test, standing alone, does not establish current impairment, deficient performance, or unsafe conduct. The guidance shall identify opportunities for individualized assessment and protection of medical information where authorized by law, while preserving applicable federal drug-use prohibitions, suitability standards, security requirements, and restrictions for safety-sensitive duties.
Not later than 180 days after the date of enactment of this Act, the Director shall complete an interagency review, in coordination with agencies responsible for federal contractor requirements, and submit a report to the Committees on Appropriations identifying existing policy barriers and recommending administrative, regulatory, statutory, or executive changes necessary to address those barriers while maintaining legitimate workplace safety and security requirements. The report shall distinguish federal personnel policies within OPM's authority from contractor requirements administered under separate federal authorities and identify the agencies responsible for implementing recommended changes.
PROPOSED COMMITTEE REPORT LANGUAGE
Federal Workplace Cannabis Testing, Disability Protections, and Employment Standards
The Committee recognizes that a positive cannabis drug test does not necessarily establish current impairment, deficient job performance, or unsafe conduct, even where other federal laws or employment policies may attach independent consequences to prohibited drug use. The Committee directs the Office of Personnel Management, in consultation with HHS, SAMHSA, and DOJ, to issue initial guidance to executive agencies within 30 days after enactment and complete an interagency policy review and submit its findings and recommendations to the Committees on Appropriations within 180 days.
(a) Testing and Employment Decisions. The review shall assess the interpretation of cannabis-positive results; pre-employment and random testing practices; medical review officer procedures; medical confidentiality; suitability determinations; and whether applicable personnel policies appropriately distinguish cannabinoid exposure from on-duty impairment, misconduct, deficient performance, and demonstrable job-related safety risks. It shall identify opportunities for individualized assessment under existing law and circumstances in which independent federal drug-use prohibitions, suitability standards, or security requirements continue to apply.
(b) Disability and Statutory Requirements. OPM shall evaluate federal employee protections under Section 501 of the Rehabilitation Act and applicable Americans with Disabilities Act standards, as well as federal contractor protections and requirements under distinct statutory authority, including Section 503 of the Rehabilitation Act. The review shall examine the implications of Executive Order 12564, federal drug-free workplace statutes and regulations, relevant Controlled Substances Act provisions, medical privacy requirements, and restrictions applicable to national-security and safety-sensitive positions. The Committee expects the review to distinguish protections available under existing federal law from changes requiring congressional or executive action, without assuming that state medical cannabis authorization automatically overrides federal requirements.
(c) Federal Personnel and Contractor Requirements. The Committee directs OPM to distinguish policies governing federal employees and applicants from requirements affecting federal contractors and their employees. OPM shall coordinate with agencies responsible for federal acquisition, contracting, and workplace testing standards to identify opportunities for consistent implementation, clarify the respective agencies' authority, and recommend appropriate changes without extending OPM's personnel authority to contractor employment decisions governed by separate federal laws and regulations.
(d) Implementation and Congressional Action. The report shall identify existing guidance that can be updated through administrative action, opportunities for individualized employment review where legally authorized, procedures for protecting confidential medical information, and scientific limitations affecting the interpretation of cannabis-positive test results. It shall also identify policies requiring regulatory, statutory, or executive changes and designate the federal agencies responsible for implementing recommended reforms.
The Committee expects the report, submitted within 180 days after enactment, to provide specific recommendations for evidence-based employment decisions, appropriate disability-related protections, and consistent federal implementation while preserving legitimate workplace safety, suitability, and national-security requirements.
DOWNLOAD PROPOSED OPM APPROPS LANGUAGE | TAKE ACTION
THE PATH FORWARD |
The priorities outlined here are part of Americans for Safe Access' coordinated FY2027 appropriations agenda across seven congressional subcommittees. Together, these requests seek to protect patients, remove discriminatory barriers, strengthen federal accountability, and establish the policies necessary to integrate medical cannabis into American healthcare.
Congress can take meaningful action through the appropriations process while laying the groundwork for comprehensive medical cannabis legislation in the 120th Congress. Patients should not have to choose between the medicine they rely on and their healthcare, housing, livelihoods, or fundamental rights. Explore ASA's complete FY2027 Medical Cannabis Appropriations Agenda to learn how these requests work together and follow the latest congressional developments.
The Path Forward: The Medical Cannabis & Cannabinoid Act
Share this page